People

Napoleone Ferrara, MD, a professor of pathology and senior deputy director for basic sciences at the University of California, San Diego, Moores Cancer Center, was named editor-in-chief of Molecular Cancer Therapeutics, effective September 1. He replaces John C. Reed, MD, PhD.

Before joining Moores Cancer Center in 2012, Ferrara held various scientific positions over 24 years at Genentech in South San Francisco, CA. Prior to that, he served as a postdoctoral research fellow at the Cancer Research Institute at the University of California, San Francisco.

Ferrara's research focuses on the mechanisms of angiogenesis. His pioneering work led to the identification of VEGF and the development and approval of two drugs: the anti-VEGF monoclonal antibody bevacizumab (Avastin) for the treatment of multiple cancers and the anti-VEGF monoclonal antibody fragment ranibizumab (Lucentis) for the treatment of age-related macular degeneration. He has received numerous awards, including the Lasker-DeBakey Clinical Medical Research Award.

Bruce G. Haffty, MD, professor and chair of radiation oncology at Rutgers' Robert Wood Johnson Medical School, New Jersey Medical School, and Cancer Institute of New Jersey in New Brunswick, began a 1-year term as president of the American Society for Radiation Oncology in September.

A graduate of Yale School of Medicine in New Haven, CT, Haffty completed his training at Yale-New Haven Hospital. Later a professor of therapeutic radiology at Yale, he served in multiple leadership roles there before moving to New Jersey in 2005.

Haffty's areas of expertise include breast cancer and head and neck cancer. His research aims to identify molecular markers of sensitivity and resistance to radiation.

For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.